DW286 is a novel broad-spectrum fluoroquinolone with excellent antipneumococcal activity. The in vitro activity of DW286 was evaluated against quinolone-susceptible and -resistant Streptococcus pneumoniae and was compared with the activities of reference compounds. Among the tested agents, DW286 showed the most potent antibacterial activity against 94 quinolone-susceptible strains [minimum inhibitory concentration (MIC) 0.008-0.03 mg/L]. Against 23 quinolone-resistant S. pneumoniae with known resistance mechanisms, DW286 also had the lowest MICs of all the tested quinolones [MIC at which 90% of isolates were inhibited (MIC(90))=0.5mg/L], followed by ciprofloxacin, sparfloxacin, moxifloxacin and gemifloxacin. The in vivo activity of DW286 against penicillin-susceptible and -resistant S. pneumoniae was more effective than that of gemifloxacin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijantimicag.2010.04.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antimicrobial activity of DW286 against Streptococcus pneumoniae.
Int J Antimicrob Agents
September 2010
School of Life Sciences, Handong Global University, Puk-ku, Pohang City, Kyungbuk 791-708, South Korea.
DW286 is a novel broad-spectrum fluoroquinolone with excellent antipneumococcal activity. The in vitro activity of DW286 was evaluated against quinolone-susceptible and -resistant Streptococcus pneumoniae and was compared with the activities of reference compounds. Among the tested agents, DW286 showed the most potent antibacterial activity against 94 quinolone-susceptible strains [minimum inhibitory concentration (MIC) 0.
View Article and Find Full Text PDFExtended spectrum of quinolone resistance, even to a potential latter third-generation agent, as a result of a minimum of two GrlA and two GyrA alterations in quinolone-resistant Staphylococcus aureus.
Chemotherapy
August 2010
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Background: This study was performed to determine the extended spectrum of quinolone resistance caused by increased mutations within the target enzymes of quinolones.
Methods: The minimum inhibitory concentrations (MICs) for ciprofloxacin, sparfloxacin, trovafloxacin and DW286 were determined against 98 ciprofloxacin-resistant Staphylococcus aureus strains. Also, PCR-amplified grlA, grlB, gyrA and gyrB DNA fragments were sequenced and amino acid changes were analyzed.
In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent.
J Antimicrob Chemother
September 2006
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Objectives: The objective of the present study was to assess the in vitro and in vivo activities of DW-224a in order to eventually use it as an antibiotic.
Methods: DW-224a was compared with DW286, ciprofloxacin and trovafloxacin. MICs of DW-224a, DW286, ciprofloxacin and trovafloxacin were determined against several groups of clinical isolates.
Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
Int J Antimicrob Agents
April 2005
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Republic of Korea.
To investigate the activity of DW286, a new fluoronaphthyridone, the quinolone resistance determining regions (QRDRs) of gyrA, gyrB, grlA and grlB genes in 64 Staphylococcus aureus clinical isolates were analyzed and the MICs of DW286 and comparator quinolones determined. Double and triple mutants in gyrA and grlA were resistant to ciprofloxacin, sparfloxacin, trovafloxacin and gemifloxacin but susceptible to DW286 (MIC 0.25-0.
View Article and Find Full Text PDFIn vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic.
Antimicrob Agents Chemother
September 2002
College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul 151-742, Korea.
The in vitro and in vivo activities of DW286, a novel fluoronaphthyridone with potent antibacterial activity, were compared with those of ciprofloxacin, gemifloxacin, sparfloxacin, and trovafloxacin. Against gram-positive bacteria, such as Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Enterococcus faecalis, the in vitro activity of DW286 was stronger than that of any other reference antibiotic. Against gram-negative bacteria, the activity of DW286 was similar to those of trovafloxacin and gemifloxacin but was weaker than that of ciprofloxacin.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!